Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 22Terminated 16Recruiting 8Active not recruiting 6Unknown 5Withdrawn 3Not yet recruiting 2Available 2Approved for marketing 1

Sponsor Class

OTHER 12INDUSTRY 2NIH 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

CNS 2

Conditions

Carcinoma, Non-Small-Cell Lung 77Breast Neoplasms 53Colorectal Neoplasms 52Neoplasms 40Advanced Solid Tumors 34Prostatic Neoplasms 31Multiple Myeloma 31Ovarian Neoplasms 28Neoplasm Metastasis 28Recurrence 27Lung Neoplasms 27Carcinoma, Hepatocellular 27Pancreatic Neoplasms 26Advanced Solid Tumor 22Small Cell Lung Carcinoma 20Leukemia, Myeloid, Acute 20Melanoma 18Endometrial Neoplasms 18Triple Negative Breast Neoplasms 17Squamous Cell Carcinoma of Head and Neck 14Lymphoma, Follicular 14Stomach Neoplasms 13Lymphoma, B-Cell 13Glioma 13Glioblastoma 13Uterine Cervical Neoplasms 12Lymphoma 11Head and Neck Neoplasms 11Solid Tumor 10Myasthenia Gravis 9

Interventions

naxitamab 1Isotretinoin 1Granulocyte-Macrophage Colony-Stimulating Factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × INDUSTRY × Neuroblastoma × Clear all
NCT06047535 2023-09-21

Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response.

SciClone Pharmaceuticals

Phase 4 Not yet recruiting
62 enrolled
CNS

Neuroblastoma

NCT05918432 2023-06-26

Determining Patterns In Study Experiences of Neuroblastoma Patients

Power Life Sciences Inc.

Not yet recruiting
500 enrolled
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡